Massively looks at the best free to play games

AOL Money & Finance

Abbott Labs to pay J&J $1.67 billion from patent lawsuit

Yesterday, pharmaceutical giant Johnson & Johnson (JNJ) said that its patent infringement lawsuit against Abbott Labs (ABT) was successful, with Abbott ordered to pay $1.67 billion because its best-selling drug, Humira, too closely resembles J&J's Remicade. The drugs are intended to treat rheumatoid arthritis by blocking a substance known as TNF, which causes inflammation. According to the Arthritis Foundation, 1.3 million Americans suffer from rheumatoid arthritis, a chronic disease. Abbott Labs sponsors the group's programs specifically related to rheumatoid arthritis.

The verdict leaves Abbott stock in a tenuous position. The healthcare sector has been in the crosshairs lately as concerns about costly medical reform swirl, with the SPDR S&P Pharmaceuticals (XPH) ETF down slightly year-to-date, compared to the nearly 5% gain on the S&P 500. Abbott Labs has underperformed both comparables, and is down 10% year-to-date.

Continue reading Abbott Labs to pay J&J $1.67 billion from patent lawsuit

Tech talk from MarketWatch

"Stocks are likely in a new downtrend," says Michael Ashbaugh. In Marketwatch's The Technical Indicator, he looks at the S&P's prospects and some drug stocks set to buck the trend.

"The S&P 500 has violated its major moving averages in the closely tracked 900 area. The recent downturn was convincingly bearish, placing the burden on market bulls to reassert the uptrend.

"After finding resistance in the 923 area, the S&P sold off sharply, edging back under its 200-day moving average, which currently holds at 900 and now marks resistance. This is bearish price action.

Continue reading Tech talk from MarketWatch

Cramer on BloggingStocks: 'Tells' of the beta trade

TheStreet.com's Jim Cramer suggests watching certain staples for hints that the flight to riskier plays is losing steam.

Will the endless "beta" trade out of slow-moving, "safe" drugs and foods and into companies like Freeport-McMoRan (NYSE: FCX) (Cramer's Take) and Caterpillar (NYSE: CAT) (Cramer's Take) ever end?

I think it won't end here, that's for certain, unless your staples stock goes to a 5% yield and the economy's macro data show a further breakdown. If we get some retail sales that are awful and some employment numbers that show a further trashing, then we are going to see a momentary blip up in stocks like Pepsi (NYSE: PEP) (Cramer's Take) and Clorox (NYSE: CLX) (Cramer's Take), but perhaps no more than that.

Continue reading Cramer on BloggingStocks: 'Tells' of the beta trade

Cramer on BloggingStocks: The seductive pull of the early cycle

TheStreet.com's Jim Cramer is seeing signs of a coming boom, but he's still being cautious here.

If you had to define the early cycle, if you had to outline what stocks should be soaring coming out of a recession into a boom and which ones should be faltering, you would have to say the action in this market in the last month is the quintessential behavioral pattern.

What are the components of the early cycle? First, it's the homebuilders. As is typical coming out of a recession, the stocks precede the bottom of housing. That's exactly what's happening with the lowest permits and highest affordability and best mortgage rates and massive inventory. Everywhere, except on Wall Street reporting, the bottom is bursting out. When you read the lead story in the Sunday Philadelphia Inquirer, and it is all about the thousands of prospective homebuyers heading south to pick up condos and homes for half of what they were worth two years ago -- or even less -- and you know that virtually no one has broken ground in the Sunshine State in a year, you can bet that the bottom's actually behind us. This housing market has wiped out all but the most stable private builders and even the public ones are merging as we know from Pulte (NYSE: PHM) (Cramer's Take) and Centex (NYSE: CTX) (Cramer's Take). So, in the next cycle, you can see some profitability developing year over year even though the new homes don't have much margin because the foreclosed homes next door are going for a song. And don't believe this won't change the dynamic of future foreclosures. In most areas, rent is higher than the interest on mortgages, so you will find that second or third job needed to stay in your home. The incentive structure's radically different than a year ago.

Continue reading Cramer on BloggingStocks: The seductive pull of the early cycle

Earnings highlights: Goldman Sachs, Google, Citigroup, GE, Intel, Nokia and more

Here are some highlights from this past week's earnings coverage from BloggingStocks:

Continue reading Earnings highlights: Goldman Sachs, Google, Citigroup, GE, Intel, Nokia and more

Charles Schwab and Abbott Labs top Q1 estimates

On Wednesday, Charles Schwab Corp. (NASDAQ: SCHW) reported that its lower first-quarter earnings easily topped analysts' estimates, and Abbott Laboratories (NYSE: ABT) said its higher first-quarter profit edged past Wall Street expectations. Shares of Schwab surged while those of Abbott Labs fell Wednesday.

San Francisco-based brokerage and investment manager Charles Schwab said it earned $218 million, or 19 cents per share, for the quarter, as compared to $305 million, or 26 cents per share, in the same period of the previous year. Total revenue fell 15% year over year to $1.11 billion.

Continue reading Charles Schwab and Abbott Labs top Q1 estimates

Abbott (ABT): An 'income machine'

"Abbott Laboratories (NYSE: ABT) is continuing its long record of rewarding shareholders," notes Alex Kolb In Zacks Elite, pointing to its 341st consecutive quarter of dividends since 1924.

"Abbott is a global, broad-based health care company that develops, manufactures and markets pharmaceuticals and medical products, including nutritionals, devices and diagnostics.

"The company employs more than 68,000 people and markets its products in more than 130 countries.

"The company recently released new data, showing that a combination of its new TriLipix triglycerides medicine and a low dose of AstraZeneca's Crestor cholesterol drug are better than the individual pills for treating heart problems.

Continue reading Abbott (ABT): An 'income machine'

Cramer on BloggingStocks: So you missed the recent run -- now what?

TheStreet.com's Jim Cramer says if you don't want to wait for a pullback, look abroad for the next leg or find values at home.

What do you do when everyone knows we have come up too far, too fast; no one knows who is actually buying; and we are going into earnings season?

What do you do when the animal spirits are taking up the market and yet other than a handful companies -- Research In Motion (NASDAQ: RIMM) (Cramer's Take), Xilinx (NASDAQ: XLNX) (Cramer's Take), Corning (NYSE: GLW) (Cramer's Take), Best Buy (NYSE: BBY) (Cramer's Take) and Taiwan Semi (NYSE: TSM) (Cramer's Take) -- almost all companies that have spoken during the "off-season" earnings reports have been dismal?

Continue reading Cramer on BloggingStocks: So you missed the recent run -- now what?

Analyst upgrades, downgrades and initiations: ABT, DPS, BDK, AMZN, GS ...

Analyst upgrades:
  • Citigroup upgraded Abbott Lab (NYSE: ABT) to Hold from Sell on valuation following the stock's recent underperformance. The firm maintains a $48 price target.
  • Deutsche Bank upgraded shares of Pepsi Bottling (NYSE: PBG) and Dr. Pepper Snapple (NYSE: DPS) to Buy from Hold as they believe carbonated soft drinks market is showing signs of stabilization. The firm raised its price target on Pepsi Bottling to $28 from $25 and on Dr. Pepper Snapple to $22 from $20.
  • Baird upgraded CommScope (NYSE: CTV) to Outperform from Neutral and raised their target to $19 from $10 as they expect fundamentals to bottom in Q1 and ramp strongly in Q2 as wireless capex outlook improves.
  • Sinopec Shanghai (NYSE: SHI) was raised to Buy from Sell at Goldman.
  • TRW Automotive (NYSE: TRW) was upgraded at JP Morgan to Neutral from Underweight.

Continue reading Analyst upgrades, downgrades and initiations: ABT, DPS, BDK, AMZN, GS ...

Abbott Labs (ABT) gains on stent study results

ABT logoAbbott Laboratories (NYSE: ABT - option chain) shares are higher today despite the surrounding market meltdown after a study released over the weekend showed the company's Xience stent showed significant safety advantages over competitor Boston Scientific's (NYSE: BSX) Taxus stent. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on ABT.

ABT opened this morning at $46.69. So far today the stock has hit a low of $46.65 and a high of $47.90. As of 11:35, ABT is trading at $47.73, up $1.13 (2.4%). The chart for ABT looks bullish and S&P gives ABT a positive 5 STARS (out of 5) strong buy ranking.

Continue reading Abbott Labs (ABT) gains on stent study results

From Good to Great to Bankruptcy: Jim Collins' book revisited

Back in 2001, Jim Collins had a monster of a business bestseller with his book Good to Great: Why Some Companies Make the Leap. . . and Others Don't. In it, Collins explored companies that have become hugely successful and found that success generally comes as a result of focusing resources on things that you're good at instead of mindlessly diversifying.

Arkansas Business writer Jeff Hankins read the book again to see how the companies profiled have weathered the downturn. The companies profiled were Abbot Laboratories (NYSE: ABT), Kroger (NYSE: KR), Kimberly-Clark (NYSE: KMB), Walgreens (NYSE: WAG), Altria (NYSE: MO), Nucor (NYSE: NUE), Pitney Bowes (NYSE: PBI), Wells Fargo (NYSE: WFC) and tragically, Fannie Mae and Circuit City. Gilette was eliminated from contention because of a merger.

Continue reading From Good to Great to Bankruptcy: Jim Collins' book revisited

Cramer on BloggingStocks: This time around, bad is just bad

TheStreet.com's Jim Cramer says picking stocks -- or worse, picking a bottom -- remains a dangerous activity.

Sometimes it is so bad that it is BAD! Don't laugh at that seeming bit of counterintuitive logic. Every investment professional knows that because of the way economic cycles and central banks work, you are often looking for signs of such stress and negativity that it is so bad it is GOOD because of what the banks can do and what a bottom looks like.

This time it hasn't worked out that way. This time, what's bad is bad and getting worse. This weekend, David Carr in The New York Times wrote an excellent piece about the mistake of looking for a silver lining, something that news media does.

Continue reading Cramer on BloggingStocks: This time around, bad is just bad

A defensive investment: Biotechnology ETFs

One of the buzzwords that is currently in vogue in the investment community is biotechnology. This is a broad-based field that covers technological applications in any biological system, meaning humans, animals, agriculture, and medicines. This is a booming science and the investment field offers many opportunities for wealth accumulation.

If you don't want to spend countless hours trying to understand not just financials, but scientific and technical jargon that biotech companies harbor, exchange-traded funds (ETFs) may be the better choice for investing in the biotechnology industry.

An ETF is similar to buying a share of a company, but instead of getting one particular company you're investing in a bundle of companies within a particular field or specialty. It's a great way to invest in something you believe in while still hedging your bets and having a bit of diversity.

Continue reading A defensive investment: Biotechnology ETFs

Abbott (ABT): Contrarian sees healthy gains

"I think 2009 will be a very tough year for the economy but an exceptional year for stocks," says Alexander Green of The Oxford Club. Here, he looks at Abbott Laboratories (NYSE: ABT).

"The company has been around for more than 120 years. It currently operates in more than 130 countries, selling hundreds of products, including Ultane (an inhaled anesthetic), the anti-infective Biaxin XL, and TriCor and Niaspan to manage cholesterol.

"However, Abbott's biggest growth driver is Humira, a blockbuster drug that targets autoimmune disorders. The drug has received FDA approval to treat a number of diseases, including rheumatoid arthritis, psoriasis and Crohn's disease.

Continue reading Abbott (ABT): Contrarian sees healthy gains

Next Page »

Symbol Lookup
IndexesChangePrice
DJIA-223.328,280.74
NASDAQ-49.201,796.52
S&P 500-26.91896.42

Last updated: July 03, 2009: 09:26 PM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

AOL Business News

BioHealth Investor Headlines

Sponsored Links

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance